ストックスクリーナーアプリを入手
31.68
1.57%
0.49
アフターアワーズ：
31.68
前日終値:
$31.19
開ける：
$31.77
24時間の取引高:
657.00K
Relative Volume:
0.78
時価総額：
$2.11B
収益：
$1.55M
当期純損益:
$-258.76M
株価収益率:
-8.1329
EPS:
-3.8953
ネットキャッシュフロー:
$-213.66M
1週間 パフォーマンス:
+11.00%
1か月 パフォーマンス:
+2.79%
6か月 パフォーマンス:
+25.47%
1年 パフォーマンス:
+57.22%
1日の値動き範囲:
$31.39
$32.44
1週間の範囲:
$27.92
$34.52
52週間の値動き範囲:
$14.40
$34.52
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Compare CLDX vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
31.68 | 2.08B | 1.55M | -258.76M | -213.66M | -3.8953 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-10-13 | 開始されました | Barclays | Underweight |
| 2025-04-28 | 開始されました | Canaccord Genuity | Buy |
| 2025-03-20 | 開始されました | Morgan Stanley | Overweight |
| 2025-02-13 | 開始されました | UBS | Buy |
| 2024-10-07 | 開始されました | Citigroup | Buy |
| 2024-09-30 | 開始されました | Goldman | Neutral |
| 2024-09-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 開始されました | Stifel | Buy |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2023-12-20 | 開始されました | TD Cowen | Outperform |
| 2023-11-10 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 開始されました | Wells Fargo | Underweight |
| 2021-09-17 | 開始されました | Jefferies | Buy |
| 2021-09-10 | 開始されました | SVB Leerink | Outperform |
| 2021-07-22 | 開始されました | Guggenheim | Buy |
| 2020-02-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-07 | 開始されました | Aegis Capital | Buy |
| 2016-03-08 | ダウングレード | Jefferies | Buy → Hold |
| 2016-03-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2016-03-07 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2016-03-01 | 開始されました | H.C. Wainwright | Buy |
| 2015-08-11 | 繰り返されました | Brean Capital | Buy |
| 2015-08-11 | 繰り返されました | Oppenheimer | Outperform |
| 2015-08-11 | 繰り返されました | ROTH Capital | Buy |
| 2015-06-02 | 繰り返されました | WBB Securities | Strong Buy |
| 2014-11-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2013-07-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-03-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2013-01-10 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2012-10-02 | 繰り返されました | Oppenheimer | Outperform |
| 2012-09-14 | 繰り返されました | Cantor Fitzgerald | Buy |
すべてを表示
Celldex Therapeutics Inc (CLDX) 最新ニュース
Celldex Therapeutics stock hits 52-week high at 32.8 USD By Investing.com - Investing.com Australia
Celldex Therapeutics stock gains after analyst upgrade - Investing.com
Celldex Therapeutics stock gains after analyst upgrade By Investing.com - Investing.com Australia
Celldex Therapeutics stock hits 52-week high at 32.8 USD - Investing.com
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year High Following Analyst Upgrade - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Wolfe Research - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Trading Up 3.7%Here's Why - MarketBeat
Breakout Zone: Can Celldex Therapeutics Inc reach all time highs this year2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Momentum - Sahm
Eventide Asset Management LLC Has $48.10 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics, Inc. $CLDX Shares Sold by Commodore Capital LP - MarketBeat
Braidwell LP Makes New Investment in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (CLDX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data Catalysts - MarketBeat
Insider Sell: Does Celldex Therapeutics Inc stock benefit from AI growth2026 Reactions & Smart Money Movement Tracker - baoquankhu1.vn
Celldex Therapeutics (CLDX) Is Up 5.7% After New Phase 2 Barzolvolimab Data in Inducible Urticaria - Sahm
Chronic Spontaneous Urticaria Pipeline Expands with 25+ - openPR.com
Chronic Spontaneous Urticaria Pipeline Expands with 25+ Therapies and 20+ Companies Advancing Next-Generation Treatments by 2026 | DelveInsight - Barchart.com
CLDX: Barzolvolimab shows strong efficacy in CSU, with key phase 3 data expected in Q4 - TradingView
Celldex Therapeutics, Inc. $CLDX Shares Purchased by American Century Companies Inc. - Defense World
Point72 files 13G/A: Celldex (CLDX) stake of 1,758,357 shares (2.6%) - Stock Titan
Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference - Defense World
Celldex Therapeutics stock hits 52-week high at $31.36 By Investing.com - Investing.com South Africa
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month HighStill a Buy? - MarketBeat
Celldex Therapeutics stock hits 52-week high at $31.36 - Investing.com
Fund Flows: Can Celldex Therapeutics Inc keep up with sector leadersJuly 2025 Trade Ideas & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Market Outlook: Will Celldex Therapeutics Inc benefit from geopolitical trends2025 Dividend Review & Precise Swing Trade Alerts - baoquankhu1.vn
New Barzolvolimab Urticaria Data And Losses Might Change The Case For Investing In Celldex Therapeutics (CLDX) - Sahm
TD Asset Management Inc Decreases Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Propel Bio Management LLC Makes New $4.01 Million Investment in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Volatility Watch: Will Celldex Therapeutics Inc benefit from government policyTrade Performance Summary & High Conviction Buy Zone Picks - baoquankhu1.vn
CLDX SEC FilingsCelldex Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Segall Bryant & Hamill LLC Buys 140,709 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Fisher Asset Management LLC Acquires 104,949 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Exploring an 83.57% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
The Goldman Sachs Group Increases Celldex Therapeutics (NASDAQ:CLDX) Price Target to $34.00 - MarketBeat
Q3 Earnings Forecast for CLDX Issued By HC Wainwright - MarketBeat
Celldex Presents Positive Data Demonstrating Barzolvolimab - GlobeNewswire
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Dis - Yahoo Finance
Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory - Insider Monkey
Assessing Celldex Therapeutics (CLDX) Valuation After Positive Barzolvolimab Phase 3 Enrollment And Phase 2 Data - simplywall.st
Celldex Stock Pre-Market (-4.7%): Profit-Taking After Positive Phase 2 Data Presentation - Trefis
Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential - Yahoo Finance
Celldex presents phase 2 data for chronic urticaria treatment By Investing.com - Investing.com Canada
Celldex Presents Additional Positive Data from Phase 2 - GlobeNewswire
What is HC Wainwright's Forecast for CLDX Q1 Earnings? - MarketBeat
CLDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Celldex Therapeutics (NASDAQ:CLDX) Announces Quarterly Earnings Results - MarketBeat
Celldex Therapeutics Rallied 24% After Clinical Update: Here’s What Analysts See Next - TIKR.com
Celldex Therapeutics stock earns 88 RS rating - MSN
Celldex Therapeutics Inc (CLDX) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):